SELLAS Life Sciences Group, Inc.

NASDAQ:SLS

Biotechnology

Healthcare
$17.95 +4.02%

+$0.31 today

Market cap
$3.66B
Beta
2.53
P/E (TTM)
-47.3
EPS (TTM)
-$0.17
52W Low $1.39High $9.51

Volume 35.53M

Average 7.79M

SLS Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

SELLAS Life Sciences Group, Inc.NASDAQ: SLS

Cash & Equivalents · Q3 FY2026 · quarter ended Sep 2026

Cash & equivalents rises 203.3% from a year ago

Cash & equivalents stood at $134.71M at the end of Q3 FY2026, up 203.3% from a year earlier and down 2.7% from the prior quarter. Over 3 fiscal years it compounded at +61.3% a year.

Context

  • Cash & equivalents amounted to 95.5% of total assets at the end of Q3 FY2026, up 9.3 pp from a year earlier.
  • Cash & equivalents increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +203.3% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterSep 2026
$134.71M-2.7% QoQ
Last fiscal yearDec 2025
$71.89M+417.7% YoY
Year agoSep 2025
$44.42M+203.3% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+203.3%——
1 year+417.7%——
3-year CAGR+61.3%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
71.89M USD
Year-over-year change
+417.7%
4-year CAGR
+35.3%

Cash & Equivalents vs competitors

How SLS compares with its peers on the latest reported figures

  • Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +203.3% is the 3rd highest of 11, against a peer median of +22.9%.
  • Cash & equivalents amounts to 95.5% of total assets for SLS, versus a peer median of 36.3%.
SLS Competitors
Cash & Equivalents for SLS and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
INCYIncyte CorporationJun 2026$3.98B USD+103.7%+1.6%50.6%
AAPGAscentage Pharma Group InternationalDec 2025CN¥2.47B CNY+99.9%+18.8%62.3%
NRIXNurix Therapeutics, Inc.Aug 2026$720.24M USD+818.2%+56.5%60.3%
IMNMImmunome, Inc.Sep 2026$212.84M USD-21.9%+218.0%42.1%
CBIOCrescent Biopharma, Inc.Mar 2026$189.16M USD+3269.4%+64.5%95.0%
IDYAIDEAYA Biosciences, Inc.Mar 2026$157.52M USD+21.2%+18.0%15.3%
SLSSELLAS Life Sciences Group, Inc.Sep 2026$134.71M USD+203.3%+61.3%95.5%
MGNXMacroGenics, Inc.Mar 2026$66.52M USD-54.3%-19.3%30.5%
AVBPArriVent BioPharma, Inc. Common StockMar 2026$62.1M USD+24.5%-34.7%17.8%
CCCCC4 Therapeutics, Inc.Mar 2026$61.27M USD+19.5%+35.9%18.6%
PRLDPrelude Therapeutics IncorporatedMar 2026$21.76M USD-46.0%+4.8%18.2%
Peer median (excluding SLS) —+22.9%+18.4%36.3%

Competitors are the stored peer set for SLS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents21.46M17.13M2.53M13.89M71.89M
Short-term Investments00000
Net Receivables00000
Inventory00000
Other Current Assets27K330K100K100K223K
Total Current Assets23.04M17.76M3.17M16.33M75.21M
Property, Plant & Equipment (Net)723K874K858K925K963K
Goodwill1.91M1.91M1.91M1.91M1.91M
Intangible Assets00000
Long-term Investments0(184K)000
Tax Assets152K184K000
Other Non-current Assets594K399K275K466K257K
Total Non-current Assets3.38M3.19M3.05M3.31M3.13M
Total Assets26.43M20.94M6.22M19.43M78.35M
Account Payables2.14M3.36M5.64M3.5M2.95M
Short-term Debt198K000544K
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities1.65M5.5M1.54M1.82M1.77M
Total Current Liabilities4.98M15.52M13.74M9.51M7.02M
Long-term Debt00000
Deferred Tax Liabilities152K184K000
Deferred Revenue (Non-current)0(184K)000
Other Non-current Liabilities336K4K000
Total Non-current Liabilities1.1M577K460K457K457K
Total Liabilities6.08M16.09M14.2M9.97M7.47M
Common Stock2K2K3K7K15K
Retained Earnings(138.6M)(179.9M)(217.24M)(248.13M)(274.99M)
Accumulated OCI00000
Other Stockholders Equity00000
Minority Interest00000
Total Equity20.35M4.85M(7.98M)9.47M70.87M
Total Debt808K945K906K1M1M
Net Debt(20.65M)(16.18M)(1.62M)(12.89M)(70.89M)

SELLAS Life Sciences Group, Inc.

NASDAQ:SLS

Intrinsic Alpha fair value

Locked

Current Price

$17.95

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.